Acute ischemic strokes (AIS) occur when blood flow to an area of the brain is blocked by a clot in a blood vessel leading to brain cell damage. Tissue plasminogen activator (tPA) therapy aims to treat AIS by dissolving clots through fibrinolytic medications that help break down blood clots. tPA therapy must be administered as soon as possible, ideally within 3-4.5 hours of stroke onset. However, timely management of neurovascular conditions like AIS remains a challenge.

The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 7 billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The large market opportunity lies in improving treatment rates for AIS through better management of neurovascular conditions. Less than 5% of AIS patients in developing regions currently receive tPA therapy due to lack of stroke infrastructure and limited availability of advanced therapies. With growing awareness, investments in stroke care facilities and training of healthcare professionals, more patients can be treated within the therapeutic window. This will help minimize disability, reduce healthcare costs associated with long-term care and enhance productivity.Addressing barriers to timely treatment can significantly increase usage of tPA therapy globally.

Porter's Analysis

Threat of new entrants: The threat of new entrants is moderate as the market requires large investments in R&D, clinical trials and product development. However, new biologics and devices provides opportunities.

Bargaining power of buyers: The bargaining power of buyers is high as buyers have many treatment options available. Buyers can negotiate on price and quality.

Bargaining power of suppliers: The bargaining power of suppliers is moderate as suppliers of drugs, devices and service provides have established relationships with buyers.

Threat of new substitutes: The threat of new substitutes is high as new treatment methods, drugs and other alternatives constantly enter the market.

Competitive rivalry: The competitive rivalry is high due to the presence of many global and local players offering a variety of treatment approaches.

SWOT Analysis

Strengths: Availability of many FDA approved treatment options. Rising awareness about stroke symptoms and emergency management.

Weaknesses: High cost of treatment and devices. Lack of standardized treatment protocols limits quality of care.

Opportunities: Growing elderly population is susceptible to strokes. Untapped emerging markets offerSCOPE for growth.

Threats: Patent cliff of blockbuster drugs. Long approval timelinesfor new therapiesand reimbursement hurdles reduce ROI.

Key Takeaways

The Global Acute Ischemic Stroke (AIS) Market Size is expected to witness high growth during the forecast period of 2023 to 2030. The global Acute Ischemic Stroke (AIS) Market is estimated to be valued at US$ 7 billion in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023-2030.

North America dominates the market currently due to high healthcare spending and infrastructure. The Asia Pacific region is poised to grow at the highest CAGR during the forecast period. This is attributed to expanding healthcare infrastructure, rising disposable incomes, growing medical tourism and increasing government focus on non-communicable diseases. China and India spend heavily on stroke management programs which will propel the market.

Key players

Key players operating in the AIS market are Boehringer Ingelheim, Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Sanofi, and Johnson & Johnson. Other prominent companies include Bayer, Biogen and Merck. These companies are engaged in developing novel drugs, devices and therapies to capture market share.

Get More Insights Here

https://www.trendingwebwire.com/acute-ischemic-stroke-ais-market-size-share-growth-outlook-2023/